Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...
Non-lethal weapons company Byrna (NASDAQ:BYRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 26% year on year to $35.25 million. Its non-GAAP profit of $0.17 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results